Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Sep 13

PMID 39271142

Authors

Johannes M A Kusters

Maarten F Schim van der Loeff

Janneke C M Heijne

Audrey J King

Hester E de Melker

Titia Heijman

Johannes A Bogaards

Birgit H B van Benthem

Affiliations

Soon will be listed here.

Abstract

Background: Between 2009-2021, bivalent human papillomavirus (HPV) vaccination was offered to girls in the Netherlands. We studied the impact of girls-only HPV vaccination on genital HPV prevalence among young adults.

Methods: PASSYON (2009-2021) is a study among sexual health clinic clients aged 16-24 years old. Questionnaires elicited data on demographics, sexual behavior, and HPV vaccination status. Genital samples were analyzed using a PCR-based assay (SPF10-LiPA25). Prevalence trends of 12 high-risk genotypes were assessed as adjusted average annual change (aAAC), estimated using Poisson generalized estimating equations models. The relation between aAAC and phylogenetic distance to HPV-16/18 was assessed by means of regression and rank correlation analysis. Data were collected from 8889 females and 3300 heterosexual males (HMs).

Results: Among females (irrespective of vaccination status), prevalences of HPV-16/18/31/33/35/45 decreased significantly over time. Increasing trends were observed for HPV-39/52/56. Among both HMs and unvaccinated females (54.3%), HPV-16/18 significantly declined, as did HPV-31 among HMs. Contrastingly, HPV-52/58 increased significantly among HMs and unvaccinated females. The type-specific aAAC correlated well with the phylogenetic distance to HPV-16/18.

Conclusions: During 12 years of girls-only bivalent HPV vaccination in the Netherlands, decreasing trends of the vaccine types and cross-protected types were observed among females. Herd protection of vaccine types was observed for HMs and unvaccinated females, and 1 cross-protected type for HMs. Increasing prevalence trends of HPV types with large phylogenetic distance to the vaccine types might indicate type replacement.

References

Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X . Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015; 51(13):1732-41. DOI: 10.1016/j.ejca.2015.06.001. View

Pimenoff V, Gray P, Louvanto K, Eriksson T, Lagheden C, Soderlund-Strand A . Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts. Cell Host Microbe. 2023; 31(11):1921-1929.e3. DOI: 10.1016/j.chom.2023.10.001. View

Shing J, Hu S, Herrero R, Hildesheim A, Porras C, Sampson J . Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022; 23(7):940-949. PMC: 9255557. DOI: 10.1016/S1470-2045(22)00291-1. View

Man I, Wallinga J, Bogaards J . Inferring Pathogen Type Interactions Using Cross-sectional Prevalence Data: Opportunities and Pitfalls for Predicting Type Replacement. Epidemiology. 2018; 29(5):666-674. DOI: 10.1097/EDE.0000000000000870. View

Kavanagh K, Pollock K, Cuschieri K, Palmer T, Cameron R, Watt C . Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017; 17(12):1293-1302. DOI: 10.1016/S1473-3099(17)30468-1. View

Murall C, McCann K, Bauch C . Revising ecological assumptions about Human papillomavirus interactions and type replacement. J Theor Biol. 2014; 350:98-109. DOI: 10.1016/j.jtbi.2013.12.028. View

Castellsague X . Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008; 110(3 Suppl 2):S4-7. DOI: 10.1016/j.ygyno.2008.07.045. View

Tota J, Jiang M, Ramanakumar A, Walter S, Kaufman J, Coutlee F . Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. PLoS One. 2016; 11(12):e0166329. PMC: 5178990. DOI: 10.1371/journal.pone.0166329. View

Bonneault M, Delarocque-Astagneau E, Flauder M, Bogaards J, Guillemot D, Opatowski L . Ability of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study. Epidemiol Infect. 2023; 151:e31. PMC: 9990403. DOI: 10.1017/S0950268823000122. View

10.

Elfstrom K, Dillner J, Arnheim-Dahlstrom L . Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015; 33(14):1673-81. DOI: 10.1016/j.vaccine.2015.02.028. View

11.

Tsang S, Sampson J, Schussler J, Porras C, Wagner S, Boland J . Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. J Natl Cancer Inst. 2020; 112(10):1030-1037. PMC: 7566371. DOI: 10.1093/jnci/djaa010. View

12.

Hoes J, Woestenberg P, Bogaards J, King A, de Melker H, Berkhof J . Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects. Clin Infect Dis. 2020; 72(5):e103-e111. PMC: 7935392. DOI: 10.1093/cid/ciaa1770. View

13.

Dickson E, Vogel R, Bliss R, Downs Jr L . Multiple-type human papillomavirus (HPV) infections: a cross-sectional analysis of the prevalence of specific types in 309,000 women referred for HPV testing at the time of cervical cytology. Int J Gynecol Cancer. 2013; 23(7):1295-302. PMC: 3882063. DOI: 10.1097/IGC.0b013e31829e9fb4. View

14.

Cameron R, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C . Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Emerg Infect Dis. 2015; 22(1):56-64. PMC: 4696690. DOI: 10.3201/eid2201.150736. View

15.

Kusters J, Obels I, van der Klis F, King A, Heijman T, Heijne J . Prevalence and risk factors for HPV seropositivity and anogenital DNA positivity among men who have sex with men: a repeated cross-sectional study. Int J Infect Dis. 2024; 145:107094. DOI: 10.1016/j.ijid.2024.107094. View

16.

Lei J, Ploner A, Elfstrom K, Wang J, Roth A, Fang F . HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020; 383(14):1340-1348. DOI: 10.1056/NEJMoa1917338. View

17.

Malagon T, Drolet M, Boily M, Franco E, Jit M, Brisson J . Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(10):781-9. DOI: 10.1016/S1473-3099(12)70187-1. View

18.

Woestenberg P, King A, van Benthem B, Donken R, Leussink S, van der Klis F . Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. J Infect Dis. 2017; 217(2):213-222. PMC: 5853250. DOI: 10.1093/infdis/jix582. View

19.

Mesher D, Panwar K, Thomas S, Edmundson C, Choi Y, Beddows S . The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016. J Infect Dis. 2018; 218(6):911-921. DOI: 10.1093/infdis/jiy249. View

20.

Brotherton J . Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Res. 2019; 7:138-140. PMC: 6465571. DOI: 10.1016/j.pvr.2019.04.004. View